Cardiac Valve Diseases and Treatments Open access Peer reviewed

Comparison of Health Status After TAVI and SAVR in Younger Low-Risk Patients with Aortic Stenosis: a NOTION-2 Analysis

A Phoksiri, Annette Maznyczka, Mikko Savontaus, Arif Khokhar and 18 more

European Heart Journal - Valvular and Structural Heart Disease | Aug 17, 2026

Scollr summary

What this paper is about

After three years, half of AS patients achieved excellent health status, regardless of TAVI or SAVR, particularly following SAVR; however, certain comorbidities predict less improvement in health status, particularly following SAVR.

Full abstract

Read the full abstract

Abstract Background Several trials have shown that transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) yield non-inferior short- and mid-term clinical outcomes in low surgical risk patients. However, information on the health status achieved by these patients is lacking. Aims To compare the incidence of excellent health status after TAVI versus SAVR in younger, low-risk patients at three-year follow-up. Methods Aortic stenosis (AS) patients aged 60-75 years with low surgical risk (n=370) were randomised to TAVI or SAVR. For this pre-defined NOTION-2 analysis, the primary safety endpoint was freedom from all-cause mortality and disabling stroke at 3 years. The primary efficacy endpoint was excellent health status, defined as Kansas City Cardiomyopathy Questionnaire (KCCQ) score >90 and New York Heart Association (NYHA) class I at three years. Results Three-year follow-up data were available for 341 patients, with health status missing in 4.3% of SAVR and 1.6% of TAVI patients. The primary safety and efficacy endpoints were comparable between TAVI and SAVR (94.6% vs. 95.1%, p=0.9; and 50.0% vs. 45.0%, p=0.35, respectively). Among patients with chronic lung disease, bicuspid AS, coronary artery disease, reduced left ventricular systolic function, or prior stroke, non-significant trends suggested a better health status following TAVI, with % risk differences of +10.5%, +13.9%, +16.0%, +18.9%, and +19.7%, respectively; however, these differences did not reach statistical significance. Conclusions After three years, half of AS patients achieved excellent health status, regardless of TAVI or SAVR. Nonetheless, certain comorbidities predict less improvement in health status, particularly following SAVR. Clinical Trial Registration: ClinicalTrials.gov Identifier NCT02825134

Direct answer

What can I do from this paper page?

Use this page to scan "Comparison of Health Status After TAVI and SAVR in Younger Low-Risk Patients with Aortic Stenosis: a NOTION-2 Analysis" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Cardiac Valve Diseases and Treatments research, save the paper, or map adjacent work.

Authors

Researchers on this paper

A Phoksiri

first | Copenhagen University Hospital

Annette Maznyczka

middle | Copenhagen University Hospital | ORCID 0000-0002-0118-5153

Mikko Savontaus

middle | Turku University Hospital

Arif Khokhar

middle | Copenhagen University Hospital

Øyvind Bleie

middle | Haukeland University Hospital | ORCID 0000-0002-7842-8707

Mariann Tang

middle | Aarhus University Hospital | ORCID 0000-0003-2861-682X

Oskar Angerås

middle | Sahlgrenska University Hospital | ORCID 0000-0002-3474-2438

Matti Niemelä

middle | Oulu University Hospital

Ingibjörg Jóna Guðmundsdóttir

middle | Reykjavík University | ORCID 0000-0001-5475-5044

Ulrik Sartipy

middle | Karolinska University Hospital

Yusuke Kobari

middle | Copenhagen University Hospital | ORCID 0000-0002-6144-9747

Mika Laine

middle | Helsinki University Hospital | ORCID 0000-0002-6906-8877

Research areas

Follow related topics

Citation

BibTeX

@article{Phoksiri2026Comparison,
  title = {Comparison of Health Status After TAVI and SAVR in Younger Low-Risk Patients with Aortic Stenosis: a NOTION-2 Analysis},
  author = {A Phoksiri and Annette Maznyczka and Mikko Savontaus and Arif Khokhar and Øyvind Bleie and Mariann Tang and Oskar Angerås and Matti Niemelä and Ingibjörg Jóna Guðmundsdóttir and Ulrik Sartipy and Yusuke Kobari and Mika Laine and Andreas Rück and Jarkko Piuhola and Evald H Christiansen and Markus Malmberg and Rune Haaverstad and B D Prendergast and Lars Søndergaard and Hans Gustav Hørsted Thyregod and Troels Højsgaard Jørgensen and Ole De Backer},
  journal = {European Heart Journal - Valvular and Structural Heart Disease},
  year = {2026},
  doi = {10.1093/ehjvshd/xwag068},
  url = {https://doi.org/10.1093/ehjvshd/xwag068}
}

FAQ

Using this paper in a discovery workflow

How do I find related work for this paper?

Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.

How can I keep up with new Cardiac Valve Diseases and Treatments research papers?

Follow Cardiac Valve Diseases and Treatments research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.

Can I cite this paper from this page?

This page includes a static BibTeX block for Comparison of Health Status After TAVI and SAVR in Younger Low-Risk Patients with Aortic Stenosis: a NOTION-2 Analysis. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.

Follow this research in Scollr

Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.

Get the app